Core Viewpoint - APA Corporation is expected to report first-quarter 2025 results on May 7, with a consensus estimate of 83 cents per share in profit and revenues of $2.2 billion [1] Group 1: Previous Quarter Performance - In the last reported quarter, APA missed the consensus earnings estimate of 97 cents, reporting adjusted earnings of 79 cents per share, while revenues of $2.5 billion exceeded estimates by nearly 10% due to contributions from the Callon Petroleum acquisition and higher production [2] - APA has beaten the Zacks Consensus Estimate in one of the last four quarters and missed in the others [3] Group 2: Estimate Revisions and Projections - The Zacks Consensus Estimate for the first-quarter earnings has been revised upward by 2.5% in the past week, indicating a 6.4% year-over-year improvement, while revenue estimates suggest a 16.3% increase from the previous year [3] Group 3: Production and Growth Factors - APA is projected to achieve strong production gains in the first quarter, with average volumes expected to reach approximately 300,000 barrels of oil equivalent per day (BOE/d), reflecting a 40% year-over-year increase from 214,050 BOE/d, driven by robust well performance and the Callon Petroleum acquisition [4] - Since 2020, APA has restructured its portfolio with over $5 billion in strategic acquisitions and $2.5 billion in divestitures, resulting in more than doubling its unconventional output in the Permian Basin and enhancing its operational efficiency [5] Group 4: Earnings Surprise Potential - The company has a positive Earnings ESP of +4.52% and a Zacks Rank of 3, indicating a likelihood of an earnings beat this season [6]

Core Insights - Williams Companies, Inc. reported revenue of $3.05 billion for the quarter ended March 2025, reflecting a 10% increase year-over-year, although it fell short of the Zacks Consensus Estimate of $3.14 billion by 2.97% [1] - The company's EPS was $0.60, slightly up from $0.59 in the same quarter last year, exceeding the consensus EPS estimate of $0.55 by 9.09% [1] Financial Performance Metrics - Northeast G&P gathering volumes were reported at 4.39 Bcf/D, surpassing the two-analyst average estimate of 4.31 Bcf/D [4] - West NGL equity sales matched the two-analyst average estimate of 6 million barrels of oil per day [4] - West gathering volumes were reported at 5.71 Bcf/D, aligning with the average estimate based on two analysts [4] - Adjusted EBITDA for the Northeast G&P segment was $514 million, exceeding the average estimate of $495.34 million [4] - Adjusted EBITDA for Transmission and Gulf of Mexico was $862 million, below the average estimate of $897.66 million [4] - Adjusted EBITDA for the West segment was $354 million, slightly below the average estimate of $366.14 million [4] - Adjusted EBITDA for Gas & NGL Marketing Services was $155 million, surpassing the average estimate of $119.41 million [4] - Modified EBITDA for Northeast G&P was $514 million, exceeding the two-analyst average estimate of $491.69 million [4] - Modified EBITDA for Transmission and Gulf of Mexico was $858 million, below the average estimate of $907.81 million [4] - Modified EBITDA for the West segment was $354 million, slightly below the average estimate of $374.29 million [4] Stock Performance - Shares of Williams Companies have returned +10% over the past month, significantly outperforming the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Company Overview - Fox Corporation is expected to report quarterly earnings of $0.96 per share, reflecting a year-over-year decline of 11.9% [3] - Revenues are anticipated to reach $4.15 billion, which is an increase of 20.5% compared to the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised 4.84% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Fox is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.53% [10][11] - Fox currently holds a Zacks Rank of 2 (Buy), suggesting a strong likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Fox exceeded the expected earnings of $0.61 per share by delivering $0.96, resulting in a surprise of +57.38% [12] - Over the past four quarters, Fox has beaten consensus EPS estimates three times [13] Industry Context - E.W. Scripps, another player in the Zacks Broadcast Radio and Television industry, is expected to report a loss of $0.23 per share, indicating a year-over-year change of -130% [17] - E.W. Scripps has an Earnings ESP of 0.00% and has not beaten consensus EPS estimates in any of the last four quarters [18]

Core Viewpoint - The market anticipates a year-over-year decline in earnings for Arcturus Therapeutics despite an increase in revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - Arcturus Therapeutics is expected to report a quarterly loss of $1.13 per share, reflecting a year-over-year change of -13% [3]. - Revenues are projected to be $38.08 million, which is a slight increase of 0.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 5% over the last 30 days, indicating a bearish sentiment among analysts [4]. - The Most Accurate Estimate for Arcturus is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -9.49% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of a positive surprise [8]. Historical Performance - In the last reported quarter, Arcturus was expected to post a loss of $0.34 per share but instead reported a loss of $1.11, resulting in a surprise of -226.47% [12]. - Over the past four quarters, Arcturus has beaten consensus EPS estimates three times [13]. Conclusion - Arcturus Therapeutics does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, suggesting caution for investors [16].

Company Overview - Lincoln Educational Services Corporation (LINC) is expected to report a year-over-year decline in earnings of 33.3%, with quarterly earnings projected at $0.04 per share, while revenues are anticipated to increase by 10.1% to $113.84 million [3][12]. Earnings Expectations - The upcoming earnings report is scheduled for May 12, and the stock may experience upward movement if the reported numbers exceed expectations, while a miss could lead to a decline [2][3]. - The consensus EPS estimate has been revised down by 38.24% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10]. Earnings Surprise Prediction - The Most Accurate Estimate for Lincoln Educational Services is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -225%, which suggests a challenging outlook for beating the consensus EPS estimate [11][10]. - The company currently holds a Zacks Rank of 4, further complicating the prediction of an earnings beat [11]. Historical Performance - In the last reported quarter, Lincoln Educational Services had an earnings surprise of +3.33%, having posted earnings of $0.31 per share against an expectation of $0.30 [12]. - Over the past four quarters, the company has surpassed consensus EPS estimates three times [13]. Industry Comparison - In comparison, Universal Technical Institute (UTI), another player in the Zacks Schools industry, is expected to report earnings of $0.12 per share, reflecting a year-over-year decline of 14.3%, with revenues projected at $197.04 million, up 7% [17]. - UTI has an Earnings ESP of 6.12% and a Zacks Rank of 3, indicating a higher likelihood of beating the consensus EPS estimate [18].

Core Viewpoint - Regenxbio (RGNX) is anticipated to report a significant year-over-year increase in earnings and revenues for the quarter ended March 2025, which could influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on May 12, 2025, with a consensus estimate of $0.41 per share, reflecting a year-over-year increase of +129.7% [3]. - Revenues are projected to reach $109.98 million, representing a substantial increase of 604.1% from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 6.26%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Regenxbio is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +57.77% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Regenxbio currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Regenxbio was expected to post a loss of $1.27 per share but actually reported a loss of $1.01, resulting in a surprise of +20.47% [12]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Sangamo Therapeutics (SGMO) is expected to report a loss of $0.11 per share for the same quarter, with a year-over-year change of +59.3% [17]. - Sangamo's revenue is projected to be $9.17 million, up 1810.4% from the previous year [17]. - Despite a recent downward revision of 23.8% in consensus EPS estimates, Sangamo has an Earnings ESP of 27.27%, but it holds a Zacks Rank of 4 (Sell), making predictions of an earnings beat uncertain [18].

Core Viewpoint - Perrigo Company plc (PRGO) is expected to exceed earnings expectations in its first-quarter 2025 report, with a consensus estimate for sales at $1.08 billion and earnings at 53 cents per share [1]. Group 1: Upcoming Earnings Expectations - The earnings surprise history shows that Perrigo has beaten estimates in three of the last four quarters, with an average surprise of 7.78% [4]. - The Zacks Consensus Estimate for sales in the Consumer Self Care Americas (CSCA) segment is $657 million, while the model estimate is $638 million [2]. - For the Consumer Self Care International (CSCI) segment, the Zacks Consensus Estimate is $432 million, and the model estimate is $434 million [2]. Group 2: Macroeconomic Impact - An update on the expected impact of macroeconomic pressures is anticipated in the upcoming earnings report [3]. Group 3: Earnings Surprise Potential - Perrigo currently has an Earnings ESP of +2.37% and a Zacks Rank of 3, indicating a good chance of delivering an earnings beat [6][7]. - Other biotech stocks with favorable combinations for potential earnings beats include CytomX Therapeutics, argenx, and Novavax, each with varying Earnings ESPs and Zacks Ranks [8][9].

Core Viewpoint - Opus Genetics, Inc. is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with the consensus outlook indicating a significant impact on the stock price based on actual results compared to estimates [1][3]. Financial Performance Expectations - The company is expected to post a quarterly loss of $0.34 per share, reflecting a year-over-year change of -17.2% [3]. - Revenues are projected to be $2.8 million, which represents a 63.7% increase from the same quarter last year [3]. Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [10]. Earnings Surprise History - In the last reported quarter, the company was expected to post a loss of $0.34 per share but instead reported a loss of $1.27, resulting in a surprise of -273.53% [12]. - Over the past four quarters, Opus Genetics has only beaten consensus EPS estimates once [13]. Industry Comparison - Cue Biopharma, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $0.14 per share for the same quarter, indicating a year-over-year change of +44% [17]. - Cue Biopharma's revenues are expected to be $2 million, up 16.3% from the previous year, with an unchanged consensus EPS estimate over the last 30 days [17][18].

Company Overview - Veren (VRN) is expected to report a year-over-year increase in earnings of +31.8% to $0.29 per share, despite a revenue decline of 12.4% to $719.9 million for the quarter ended March 2025 [3][12] - The stock's price movement will largely depend on how actual results compare to consensus estimates, with a potential for higher stock prices if results exceed expectations [1][2] Earnings Estimates and Revisions - The consensus EPS estimate for Veren has been revised 25% higher in the last 30 days, indicating a bullish sentiment among analysts [4] - The Most Accurate Estimate for Veren is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +13.79%, suggesting a strong likelihood of beating the consensus EPS estimate [10][11] Earnings Surprise History - In the last reported quarter, Veren exceeded expectations by delivering earnings of $0.29 per share against an expected $0.24, resulting in a surprise of +20.83% [12] - Over the last four quarters, Veren has beaten consensus EPS estimates only once, indicating a mixed performance history [13] Industry Context - In the Zacks Oil and Gas - Integrated - Canadian industry, Cenovus Energy (CVE) is expected to report earnings of $0.29 per share, reflecting a year-over-year decline of -37%, with revenues projected at $9.55 billion, down 3.9% [17] - Cenovus has seen a 1.6% downward revision in its consensus EPS estimate over the last 30 days, and its Earnings ESP is currently at 0.00%, making it difficult to predict a beat against consensus estimates [18]

Core Viewpoint - The market anticipates Costamare (CMRE) will report a year-over-year decline in earnings due to lower revenues for the quarter ended March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Costamare is expected to post quarterly earnings of $0.52 per share, reflecting a year-over-year decrease of 17.5% [3]. - Revenues are projected to be $412.67 million, down 13.2% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Costamare is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +6.80% [10][11]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a potential earnings beat, especially when combined with a strong Zacks Rank [8]. - However, Costamare currently holds a Zacks Rank of 4, complicating the prediction of an earnings beat despite the positive Earnings ESP [11]. Historical Performance - In the last reported quarter, Costamare exceeded the expected earnings of $0.66 per share by delivering $0.69, resulting in a surprise of +4.55% [12]. - The company has beaten consensus EPS estimates in each of the last four quarters [13]. Industry Context - In the Zacks Transportation - Shipping industry, Ardmore Shipping (ASC) is expected to report earnings of $0.15 per share, indicating a year-over-year decline of 83.7% [17]. - Ardmore Shipping's consensus EPS estimate has been revised 37.8% lower in the last 30 days, leading to an Earnings ESP of -10.35% [18].